Please login to the form below
epigenetics
This page shows the latest epigenetics news and features for those working in and with pharma, biotech and healthcare.
GSK: we won’t be splitting up any time soon
Particularly in the spotlight is oncology, where GSK has cell therapy candidates, epigenetic modulators and antibodies targeting immune cells.
Latest news
-
AstraZeneca to explore link between epigenetics and respiratory diseases
Epigenetics are changes in the expression of genes attributed to lifestyle factors affecting the body, but do not alter the DNA sequence. ... To date, research into epigenetics has been largely focused on cancer, but the collaborators believe it houses
-
Biogen buys into Rodin's Alzheimer's candidate
And may acquire the epigenetics-focused Massachusetts firm. Biogen has signed a deal with Atlas Venture-backed Rodin Therapeutics that could result in the acquisition of the Alzheimer's disease-focused ... Biogen has its own research programme in
-
Novartis' Farydak gets nod for myeloma in Europe
Novartis says its approval marks "the first time an HDAC inhibitor with epigenetic activity is available in the EU," providing a much-needed additional line of therapy for patients with aggressive
-
Celgene to acquire biotech firm Quanticel Pharmaceuticals
Through the agreement, Celgene will have full access to Quanticel's proprietary platform for the single-cell genomic analysis of human cancer, alongside Quanticel's lead programmes that target specific epigenetic
-
Novartis pays $16bn for GSK's oncology portfolio
on cancer immunotherapy, epigenetics and tumour environment.
More from news
Approximately 1 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Deal Watch November 2016
licence, collaboration. 207.5. Proterosos biostructures/ Merck &Co (MSD). second collaboration to develop small molecules against an additional epigenetic target for various cancers.
-
Deal Watch January 2016
Tensha has developed an epigenetic technology that disrupts bromodomain and extra terminal domain (BET) proteins in order to develop potential treatments for cancer. ... 535. Rodin/ Biogen. Collaboration. Multi-year neuronal epigenetics research
-
Deal Watch October 2015
Proteros' epigenetics technology and structure guided discovery platform for oncology targets (discovery).
-
Pharma deals in August 2015
This situation occurred when Genentech/Roche elected not to go further with their option to acquire the epigenetics drug discovery company, Constellation Pharmaceuticals.
-
Pharma deals in April 2015
Resminostat has an innovative epigenetic mechanism of action that potentially enables the compound to be deployed as a novel, targeted tumour therapy Menarini is paying $102m (95m) in upfront fees and
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Professor Thomas Cech joins Storm Therapeutics
mature into a world leading therapeutics company targeting RNA epigenetic modulation.”.
-
Storm Therapeutics bolsters its team
As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells. ... Keith Blundy, chief executive officer of Storm Therapeutics,
-
Storm Therapeutics strengthens its board
RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. ... We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”.
-
Rubius Therapeutics strengthens senior team
He most recently served as the senior vice president and head of the cancer epigenetics department at GlaxoSmithKline, where he was responsible for overall strategy, as well as identification and validation ... of new epigenetic targets and advancing
-
Paul Stockdale joins Oxford BioDynamics as CFO
A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.
More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.
Featured jobs
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Associate Director
-
£75, 000-90, 000
-
Account Director
-
Competitive Salary Offered
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Director, Medical Education
-
Salary TBC
-
Senior Account Manager
-
Competitive Salary Offered
-
Senior Medical Writer
-
Salary TBC
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Business Director
-
Competitive Salary Offered
-
Medical Writer
-
Salary TBC
-
Account Manager / Account Director
-
Competative
- Global Business Development Director – Health Education
-
excellent commission
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
Subscribe to our email news alerts
- China’s clinical trial shake-up
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Novartis forges AI alliance with Oxford University
- FDA adcomm split on Sanofi’s type 1 diabetes drug
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
PMHub
infill healthcare communication
infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...
Latest intelligence
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
Quick links
Infographics
